申请人:OliPass Corporation
公开号:US11162104B2
公开(公告)日:2021-11-02
The current invention provides peptide nucleic acid derivatives targeting the 3′ splice site of exon 4 in the human SCN9A pre-mRNA. The peptide nucleic acid derivatives potently induce SCN9A mRNA splice variant(s) lacking the SCN9A exon 4 in cells, and are useful to safely treat pains or conditions involving Nav1.7 activity.
本发明提供了靶向人 SCN9A 前 mRNA 第 4 外显子 3′剪接位点的多肽核酸衍生物。多肽核酸衍生物能有效诱导细胞中缺乏 SCN9A 第 4 号外显子的 SCN9A mRNA 剪接变体,可用于安全治疗涉及 Nav1.7 活性的疼痛或病症。